Enasidenib

Overview

Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes , with IC 50 s of 100 and 400 nM against IDH2 R140Q and IDH2 R172K , respectively.

Application

Products | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Isocitrate Dehydrogenase (IDH)

Product Information

• Catalog No.: HY-18690
• CAS No.: 1446502-11-9
• Molecular Formula: C19H17F6N7O
• Molecular Weight: 473.38
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: 2.08 mg/mL (4.39 mM); Suspended solution; Need ultrasonic and warming
• Availability: In-stock

Source

Original product source